 |
|
Sexual function affected by stem cell transplant according to long-term study
September 19, 2007A long-term study found that a type of stem cell transplant used for patients with life-threatening diseases, such as leukemia and lymphoma, results in decreased sexual function and activity for recipients. Further, males are likely to recover from these changes over time, while the sexuality of female patients remains compromised. In addition, neither male nor female long-term cancer survivors regained levels of sexual activity and function equal to those of their peers who have not had cancer, according to a Blood First Edition Paper prepublished online today. Blood is the official journal of the American Society of Hematology.
"Survival without a sex life should not be what cancer survivors settle for or what health-care professionals consider a successful outcome of cancer treatment," stated lead study author, Karen Syrjala, PhD, co-director of the Survivorship Program at the Fred Hutchinson Cancer Research Center. "Sexual dysfunction in survivors of cancer needs to become a priority for research funding and a routine topic of discussion between doctors and their patients after cancer treatment."
In an allogeneic hematopoeitic stem cell transplantation, patients with diseases of the blood, bone marrow, or certain types of cancers receive an infusion of new stem cells from a sibling or tissue-matched unrelated donor to replace the damaged or destroyed cells in their bone marrow needed for the production of blood cells. Before the transplant, high-dose chemotherapy is administered to kill residual cancer cells and to suppress the immune system so that the patient's body will not reject the new tissue.
The results of questionnaires on sexual function were reported for 161 patients scheduled to receive this procedure at the Fred Hutchinson Cancer Research Center in Seattle. The patients ranged in age from 22-64 years with an average age of 41 and a nearly even split by gender.
Before the transplant, study participants completed an assessment of their sexual health at the clinic, and, after the procedure, surveys were mailed to the patients to complete at the six-month interval and after one, two, three, and five years. The response rate to the questionnaire averaged 84 percent with all participants completing one or more surveys during the five-year period.
The surveys included 37 questions in the areas of interest, desire, arousal, orgasm, satisfaction, activity, relationship, masturbation, and sexual problems. The male and female versions had the same content except for variations in the problems section according to sex. In addition, those who were not sexually active were provided with a list of possible reasons and asked to mark as many as applied.
At five years, the assessments were compared against a control group consisting of siblings or friends of the study patients that were within five years of the participant's age and who were of the same gender, ethnicity, race, and educational background. If a local match was not available, the researchers recruited volunteers from the community that fit the criteria.
At the six-month mark, both genders had decreased sexual activity, but, by one year, sexual activity for the majority of the men (74 percent) had recovered to the levels seen at the beginning of the study. For women, recovery of sexual activity took longer, with just over half (55 percent) returning to sexual activity after two years. Though sexual activity was restored for these patients, for those who were sexually active at the five-year mark, 46 percent of the men and 80 percent of the women reported problems that disrupted sexual function.
According to the researchers, sexual dysfunction in transplant patients is likely caused by systemic therapies, such as total body irradiation and chemotherapy drugs known as alkylating agents, which are known to permanently damage endocrine glands that play a critical role in the development and regulation of the reproductive system.
In addition, chronic graft-versus-host disease (GVHD), a common complication of transplantation experienced by 65 percent of the patients in this study, may cause shrinkage of the vaginal tissues and changes to the vaginal lining that can contribute to sexual dysfunction in women. For males, testosterone levels and the cavernosal arteries of the penis are affected, eroding libido and erectile function.
Lack of interest or libido explained sexual inactivity in part for nearly 20 percent of female survivors at both six months and five years, suggesting that this problem did not improve over time. In contrast, for males, lack of interest or libido as a reason for inactivity declined from 14 percent to 6 percent between six months and five years.
At the five-year mark, the rates of sexual activity and sexual function for both male and female patients were below those of the control group, suggesting that they did not fully recover from the effects of the cancer itself or cancer treatments. Further studies are needed to determine if hormone treatments for both sexes or other therapies will help these patients achieve the same sexual function and activity as their peers.
The researchers also recommend that patients undergoing stem cell transplantation be made aware of potential changes in their sexuality and given resources to address these needs to help improve long-term quality of life. Men may benefit from reassurance that erectile function and sexual desire should improve by one to two years after treatment, but that methods such as testosterone replacement, erectile-function medications, and other adaptive strategies can be considered if problems continue. For women, methods that focus on communication with their partners about changes in sensation, strategies for enhancing libido, and use of vaginal lubricants, dilators, or vibrators to assist with adapting to genital changes may help to maintain sexual responsiveness.
American Society of Hematology
The results of questionnaires on sexual function were reported for 161 patients scheduled to receive this procedure at the Fred Hutchinson Cancer Research Center in Seattle. The patients ranged in age from 22-64 years with an average age of 41 and a nearly even split by gender.
Before the transplant, study participants completed an assessment of their sexual health at the clinic, and, after the procedure, surveys were mailed to the patients to complete at the six-month interval and after one, two, three, and five years. The response rate to the questionnaire averaged 84 percent with all participants completing one or more surveys during the five-year period.
The surveys included 37 questions in the areas of interest, desire, arousal, orgasm, satisfaction, activity, relationship, masturbation, and sexual problems. The male and female versions had the same content except for variations in the problems section according to sex. In addition, those who were not sexually active were provided with a list of possible reasons and asked to mark as many as applied.
At five years, the assessments were compared against a control group consisting of siblings or friends of the study patients that were within five years of the participant's age and who were of the same gender, ethnicity, race, and educational background. If a local match was not available, the researchers recruited volunteers from the community that fit the criteria.
At the six-month mark, both genders had decreased sexual activity, but, by one year, sexual activity for the majority of the men (74 percent) had recovered to the levels seen at the beginning of the study. For women, recovery of sexual activity took longer, with just over half (55 percent) returning to sexual activity after two years. Though sexual activity was restored for these patients, for those who were sexually active at the five-year mark, 46 percent of the men and 80 percent of the women reported problems that disrupted sexual function.
According to the researchers, sexual dysfunction in transplant patients is likely caused by systemic therapies, such as total body irradiation and chemotherapy drugs known as alkylating agents, which are known to permanently damage endocrine glands that play a critical role in the development and regulation of the reproductive system.
In addition, chronic graft-versus-host disease (GVHD), a common complication of transplantation experienced by 65 percent of the patients in this study, may cause shrinkage of the vaginal tissues and changes to the vaginal lining that can contribute to sexual dysfunction in women. For males, testosterone levels and the cavernosal arteries of the penis are affected, eroding libido and erectile function.
Lack of interest or libido explained sexual inactivity in part for nearly 20 percent of female survivors at both six months and five years, suggesting that this problem did not improve over time. In contrast, for males, lack of interest or libido as a reason for inactivity declined from 14 percent to 6 percent between six months and five years.
At the five-year mark, the rates of sexual activity and sexual function for both male and female patients were below those of the control group, suggesting that they did not fully recover from the effects of the cancer itself or cancer treatments. Further studies are needed to determine if hormone treatments for both sexes or other therapies will help these patients achieve the same sexual function and activity as their peers.
The researchers also recommend that patients undergoing stem cell transplantation be made aware of potential changes in their sexuality and given resources to address these needs to help improve long-term quality of life. Men may benefit from reassurance that erectile function and sexual desire should improve by one to two years after treatment, but that methods such as testosterone replacement, erectile-function medications, and other adaptive strategies can be considered if problems continue. For women, methods that focus on communication with their partners about changes in sensation, strategies for enhancing libido, and use of vaginal lubricants, dilators, or vibrators to assist with adapting to genital changes may help to maintain sexual responsiveness.
American Society of Hematology
Stem Cell Transplant Current Events and Stem Cell Transplant News RSSA double-barreled immune cell approach for neuroblastoma
Adding an artificial tumor-specific receptor to immune system cells called T-lymphocytes that target a particular virus extended and improved the cells' ability to fight a form of childhood cancer called neuroblastoma, said researchers form Baylor College of Medicine and Texas Children's Hospital in a report that appears online today in the journal Nature Medicine.
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients.
Predicting the risk of a common fungal infection after stem cell transplantation
In silico genetic analysis in mice has led to the discovery of a gene affecting susceptibility to a severe fungal infection in transplant recipients.
Gene mutation improves leukemia drug's effect
Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia makes the disease more susceptible to high doses of a particular anticancer drug.
PET and Bioluminescent Imaging Aid Evaluation of Stem Cells' Potential for New Ways to Treat Disease
Using positron emission tomography (PET) imaging with bioluminescence-the light produced by a chemical reaction within an organism-researchers are starting to understand the behavior of transplanted or implanted stem cells that may one day be used to develop new treatments for disease.
Penn's Abramson Cancer Center part of major phase III study for myeloma
Researchers from the Abramson Cancer Center of the University of Pennsylvania announced today that findings from two large, international clinical trials show unprecedented survival for patients with multiple myeloma, a cancer that occurs in the blood-making cells of bone marrow.
Gene profiling can single out the worst cases of multiple myeloma and guide therapy
Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potentially guide therapy in the future.
T vs. B: Re-engineered human T cells effectively target and kill cancerous B cells
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).
Stem cell transplantation procedure results in long-term survival for amyloidosis patients
Researchers from the Stem Cell Transplant Program and the Amyloid Treatment and Research Program at Boston University Medical Center (BUMC) have found that high-dose chemotherapy and blood stem cell transplantation can result in long-term survival for patients diagnosed with primary systemic light chain (AL) Amyloidosis.
Advanced therapy offers cure for relapsed cancer patient
Testicular cancer patients who do not respond to traditional therapy can be cured with high-dose chemotherapy and a stem cell transplant.
More Stem Cell Transplant Current Events and Stem Cell Transplant News Articles
 | Bone Marrow and Blood Stem Cell Transplants: A Guide For Patients by Susan Stewart Bone Marrow and Stem Cell Transplants: A Guide for Patients is the next generation of Susan K. Stewart's groundbreaking 1992 book Bone Marrow Transplants: A Book of Basics for Patients. This new 228 paage guide combines solid medical information with the voices of people who have been through a transplant. Comprehensive and easy-to-read, Bone Marrow and Blood Stem Cell Transplants: A Guide for... |
 | Autologous Stem Cell Transplants: A Handbook for Patients by Susan K. Stewart This book is an excellent guide for patients and families facing an autologous stem cell transplant. It describes what's involved in going through a transplant, both physically and emotionally, and provides guidance on how to cope with potential side... |
| Survivors' guide for bone marrow/stem cell transplant: What to expect and how to get through it by Keren Stronach | |
 | Stems of Life Picked from the Garden of Survival by Virginia, E. Hansen The author developed an itch and various odd sensations, indicating Hodgkin's Lymphoma cancer. In May 2002, she relapsed and standard chemotherapy no longer worked. In a last ditch effort, she was given a stem cell transplant that saved her... |
 | Over 140 Things You Need to Know about Your Autologous Bone Marrow or Stem Cell Transplant Book Description Over 140 Things You Need to Know about Your Autologous Bone Marrow or Stem Cell Transplant was written by Mark Patton after his fifth transplant. He has had two bone marrow transplants (BMTs) and three peripheral blood stem cell transplants (PBSCTs) since he was diagnosed with multiple myeloma in 1991. Mark now claims the tongue-in-cheek title of The World s Most Transplanted... |
| Blood Stem Cell Transplants Blood derived stem cells are used increasingly to treat cancer. This book examines the latest information in this new and rapidly emerging field and assesses its future therapeutic role. The readable and well structured text opens with an overview of the concepts behind and advantages of blood stem cell transplants. Detailed concepts of their use are later expanded upon and critically reviewed by... | |
| The Rebirth: Memoirs of a Stem Cell Transplant | |
| My Detour on Life's Highway: The Story of a Stem Cell Transplant Survivor by Rosemary Champagne In 1985, businesswoman Rosemary Champagne was diagnosed with lymphoma. After several years of traditional treatment, it was determined that a relatively new procedure where healthy stem cells, harvested from the body to replace cancerous cells, was Champagne's best chance for survival. This book is her courageous story of treatment and recovery. "Because of a stem cell transplant, I have a second... | |
| New technique allows doctors to perform stem cell transplants despite significant mismatches.: An article from: Transplant News This digital document is an article from Transplant News, published by Transplant Communications, Inc. on October 30, 1998. The length of the article is 613 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
| Progress seen with stem cell transplant for systemic sclerosis.(Clinical Rounds): An article from: Skin & Allergy News by Nancy Walsh This digital document is an article from Skin & Allergy News, published by Thomson Gale on June 1, 2007. The length of the article is 804 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Progress... |
| © 2008 BrightSurf.com |